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Available online 18 October 2013Salmonid alphavirus is the aetological agent of pancreas disease (PD) in marine Atlantic
salmon, Salmo salar, and rainbow trout, Oncorhynchus mykiss, with most outbreaks in Norway
caused by SAV subtype 3 (SAV3). This atypical alphavirus is transmittedhorizontally causing a
significant economic impact on the aquaculture industry. This histopathological and
proteomic study, using an established cohabitational experimental model, investigated the
correlation between tissue damageduring PD and a number of serumproteins associatedwith
these pathologies in Atlantic salmon. The proteins were identified by two-dimensional
electrophoresis, trypsin digest and peptide MS/MS fingerprinting. A number of humoral
components of immunitywhichmay act as biomarkers of the diseasewere also identified. For
example, creatine kinase, enolase and malate dehydrogenase serum concentrations were
shown to correlate with pathology during PD. In contrast, hemopexin, transferrin, and
apolipoprotein, amongst others, altered during later stages of the disease and did not correlate
with tissue pathologies. This approach has given new insight into not only PD but also fish
disease as a whole, by characterisation of the protein response to infection, through
pathological processes to tissue recovery.
Biological significance
Salmonid alphavirus causes pancreas disease (PD) in Atlantic salmon, Salmo salar, and has a
major economic impact on the aquaculture industry. A proteomic investigation of the
change to the serum proteome during PD has been made with an established experimental
model of the disease. Serum proteins were identified by two-dimensional electrophoresis,
trypsin digest and peptide MS/MS fingerprinting with 72 protein spots being shown to alterKeywords:
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Pathology
2-Dimension electrophoresis
Serum proteome
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424 J O U R N A L O F P R O T E O M I C S 9 4 ( 2 0 1 3 ) 4 2 3 – 4 3 6significantly over the 12 week period of the infection. The concentrations of certain
proteins in serum such as creatine kinase, enolase and malate dehydrogenase were shown
to correlate with tissue pathology while other proteins such as hemopexin, transferrin, and
apolipoprotein, altered in concentration during later stages of the disease and did not
correlate with tissue pathologies. The protein response to infection may be used to monitor
disease progression and enhance understanding of the pathology of PD.
© 2013 The Authors. Published by Elsevier B.V. All rights reserved.1. Introduction
First described in farmed Atlantic salmon, Salmo salar L., from
Scotland, in 1976, pancreas disease (PD) is characterized by
lethargy and other behavioural modifications, sequential acute
necrosis of the pancreatic acinar cells, cardiomyopathy and
skeletal muscle necrosis, fibrosis and degeneration whilst
damage to the kidney, liver and brain can also be observed in
some individuals [1–3]. Subsequent to the initial histopath-
ological characterization of PD in Scotland the disease was
described in other regions including: North America [4], Norway
[5], Ireland [6], France and Spain [7]. It was not until 1995,
however, that the aetiological agent of the disease was
discovered and given the name salmon pancreas disease virus
(SPDV) [8]. Two years later, the aetiological agent of sleeping
disease (SD), which shares the same pathogenesis as PD, in
freshwater rainbow trout, Oncorhynchus mykiss, was also
isolated and named sleeping disease virus (SDV) [9]. Further
analysis of these viruses revealed that both SDV and SPDV
possessed phenotypic and genotypic similarity with serological
cross-reactivity also being observed [10]. Thus SDV and SPDV
were identified as two related isolates of the same virus and the
species name salmonid alphavirus (SAV) proposed.
Knowledge of SAVs has grown considerably since their
identification. For instance, there are at present six closely related
subtypes defined [11,12]. These differ not only in geographical
location [13,14] but also between aquatic environments. For
example, SAV 2 is the only subtype commonly detected in
freshwater systems, causing SD in freshwater trout, though it
has also been identified in salmon in the marine environment
[13]. In addition, recent work has suggested that there may be
differences between strains in the infection dynamics [15] and
minor differences in prevalence and severity of tissue damage
[16].
Natural outbreaks of PD in Atlantic salmon have only been
reported in the seawater phase of production [3]. In light of
this, it would seem that if vertical transmission does occur its
impact would be negligible [17], with horizontal transmission
being by far the most important means of virus spread [18,19]
with shedding of mucus and faeces being recently described
as transmission routes for SAV [15].
Proteomics is a well-established post-genomic tool which
allows investigation of complex biological systems involved in
pathology and physiology in model organisms and livestock,
such as; fish, cattle and pigs [20–22]. However, despite
some notable exceptions, aquaculture research using this
methodology has had limited application in fish biology [23].
Furthermore, there have been fewer attempts to determine
the relationship between pathology and proteome. Therefore,
this study aims to investigate the modification of the Atlantic
salmon serum proteome profile caused by PD, using SAV3 asthe aetiological agent, in order to identify serum biomarkers
of the disease in relation to tissue damage as assessed by
histopathology. In addition, this study explores serum
proteome changes over a 12 week period to highlight
biomarkers of the most critical period of pathology and
disease recovery. Virology, serology and RT-PCR were used to
experimentally demonstrate the horizontal spread of SAV and
to confirm the virus was the aetiological agent of observed
pathology.2. Materials and methods
2.1. Fish husbandry and challenge
The following experimental procedure was approved by the
Norwegian National Animal Research Authority (NARA) prior
to the trial commencing.
Seven hundred Atlantic salmon (Salmo salar) parr of mean
weight 30 g, (<15% CV) were randomly distributed into
duplicate 1 m3 tanks (=1400 total fish). Following six week
acclimatisation the fish were fed to a target of 1.5% body
weight per day. Commercial formulated feed was offered to
the fish throughout the experiment (CPK 2 mm; 3 mm, BioMar
AS, Denmark). Water temperature was maintained at 12–14 ±
1 °C, water flow 0.8 l/kg min, and light/dark regime 12:12 h.
After 42 days, 60 fish from each duplicate tank were
transferred into triplicate 0.6 m3 tanks and water temperature
was increased to 14 ± 1 °C. Additional fish from the duplicate
tanks were maintained separately to be used as Trojan
shedders i.e. twelve challenge tanks all containing 120 fish
(with Trojan fish to be added later). Naïve fish to be used as
Trojans were marked by clipping their adipose fin and
injected with SAV 3 infected CHSE cell culture supernatant
at ca. 105 TCID/fish into their intraperitoneal cavity. Thirty
inoculated Trojans were added to each of the challenge tanks
6 days after their assembly. The challenge and time course of
sampling were staggered between replicate tanks over three
consecutive days and kept constant at each sampling.
Cohabitant fish were sampled at 0, 2, 3, 4, 5, 6, 8, 10 and
12 weeks post challenge (wpc). At each time point 9 fish per
tank were killed by lethal overdose of anaesthetic benzocaine
chloride (Apotekproduksjon AS, Oslo, Norway), 1 g/10 L water
for 5 min being used and blood collected in non-heparinised
vacutainers for analysis of serum biochemistry and serological
and virological analysis. From 6 of these fish, pyloric caecae and
pancreas (hereafter referred to as pancreas), heart and
skeletal muscle tissue were processed from standardised
locations for histology. Fish sampled at time point 0 were
removed from the tanks before the addition of Trojan
shedders.
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Assessment of virology was carried out in order to confirm
that SAV was absent at the start of the trial and subsequently
to confirm that any changes in histopathology and the serum
proteome were caused by SAV infection and thus PD. Virus
neutralization (VN) testing, virus isolation and real-time
RT-PCR testing were carried out as previously described [15].
2.3. Histopathology
Tissues for histology from the salmon were immediately
fixed in 3.5% v/v formaldehyde in buffered saline pH 7.0
(4.0 g NaH2PO4.2H2O, 6.5 g Na2HPO4.2H2O) prior to further
processing by standard paraffin wax techniques, sectioned
and stained with haematoxylin and eosin (H & E). The tissue
sections were examined by an experienced pathologist and
a scoring system was used to semi-quantify the distribution
and severity of the tissue lesions in the pancreas, heart and
skeletal muscle as used in previous studies [16,24]. A mean
score was calculated at each time point for tissues to firstly
demonstrate the pathological damage caused by SAV
infection/PD and also to examine the relationship between
tissue damage and the serum proteome (see Section 2.5 for
further information).
2.4. Sample preparation and two-dimensional
electrophoresis (2DE)
One microlitre of each serum sample collected from each fish
sampled at each time point was pooled according to week to
create pooled samples for the analysis of changing protein
composition throughout the time course. The protein concen-
tration of the pooled samples was determined by Bradford assay,
using Bradford Reagent (Sigma-Aldrich, Poole UK), in accordance
with the manufacturer's protocol. Concentrations were used to
allow dilution of samples to an equal protein loading (of 208 μg)
for 2DE protein separation by isoelectric focusing based on
isoelectric point (pI) and sodium dodecyl sulphate poly-
acrylamide gel electrophoresis (SDS-PAGE) based on molecular
weight (Mw). Three replicate 2DE gels were run of the pool of
samples from each time point. Separation by pI was carried out
using 11 cm immobilized pH Gradient (IPG) strip with a pH range
of 3 to 10 (BioRad,HemelHempstead, UK). After protein loading of
the IPG strips, with serum diluted in a rehydration buffer (8 M
Urea, 2% CHAPS, 50 mM DTT, 0.2% Bio-Lyte®) (BioRad, Hemel
Hempstead, UK) and covered in 500 μl of mineral oil, a combined
rehydration and focusing step was carried out over 17 h with a
total of 35,000 V-h. The IPG strips were removed, oil drained and
then treated with two equilibration buffers both made from a
stock solution comprised of 6 M urea, 0.375 M Tris–HCl, pH 8.8,
2% (w/v) SDS, 20% (v/v) glycerol, the first of these containing 2%
(w/v) dithiothreitol (Sigma-Aldrich, Poole, UK) to reduce the
proteins and subsequently the alkylating agent iodoacetamide
at 2.5% (w/v) (Sigma-Aldrich, Poole, UK). IPG strips were then
placed onto Criterion SDS-PAGE gels and submerged in XT Mops
running buffer and subjected to electrophoresis at 200 V for one
hour (Bio-Rad, Hemel Hempstead UK). Subsequently gels were
stained in Coomassie brilliant blue G-250 dye 0.1% (w/v) in
de-stain solution for 1 h and then de-stained using a solution ofmethanol:water:acetic acid, (4:5:1) overnight, scanned and saved
in 16-bit grey TIFF format images for gel image analysis.
2.5. Gel image analysis
Images were uploaded onto ‘Nonlinear Progenesis SameSpots’
2D gel image analysis software (Nonlinear Dynamics,
Newcastle, UK) which was used to identify protein spots
which were differentially expressed through time (inferred by
the programme by normalised spot intensities). Initial results
were filtered using the programme's statistical analysis
function, with only those with a power value of >80% and
ANOVA significance score of <0.05 between groups of replicate
gels, being chosen for protein identification. To investigate the
relationship among different time-points and different proteins
with respect to spot intensity, the dataset was analysed using
cluster analysis. ArrayStar software (DNASTAR, Madison, WI,
USA) was used to perform Hierarchical Cluster Analysis based
on Euclidean distance and the results were illustrated in the
form of a heat map.
Spot information (profiles) was also used in a general
linear model procedure in SAS version 9.3 (SAS Institute, Cary,
N. Carolina) for regression analysis. Each spot was regressed
on the mean value of each tissue's histopathological score at
each sampling time point in a separate model. Therefore, the
probability that a protein spot increased or decreased in
intensity in association with tissue damage as determined by
histopathology was determined.
2.6. Spot preparation and mass-spectrometry
Chosen protein spots were excised manually by scalpel and
placed in individual vials to be subjected to in-gel digestion for
protein extraction prior to identification viamass spectrometry
analysis. Gel pieces were washed with 100 mM NH4HCO3 for
30 min and then for a further hour with 100 mM NH4HCO3 in
50% (v/v) acetonitrile. After eachwashall solventwasdiscarded.
Gel plugs were then dehydrated with 100% acetonitrile for
10 min prior to solvent being removed and dried completely by
vacuum centrifugation. Dry gel pieces were then rehydrated
with 10 μl trypsin at a concentration of 20 ng/μl in 25 mM
NH4HCO3 (Cat No. V5111, Promega, Madison, WI, USA) and
proteins allowed to digest overnight at 37 °C. This liquid was
transferred to a fresh tube, and gel pieces washed for 10 min
with 10 μl of 50% acetonitrile. This wash was pooled with the
first extract, and the tryptic peptides dried to completion.
Tryptic peptides were solubilized in 0.5% (v/v) formic acid and
fractionated on a nanoflow uHPLC system (Thermo RSLCnano)
before analysis by electrospray ionisation (ESI)mass spectrometry
on an Amazon ion trap MS/MS (Bruker Daltonics). Peptide
separation was performed on a Pepmap C18 reversed phase
column (LC Packings), using a 5–85% v/v acetonitrile gradient (in
0.5% v/v formic acid) run over 45 min. at a flow rate of 0.2μl/min.
Mass spectrometric (MS) analysis was performed using a
continuous duty cycle of survey MS scan followed by up to five
MS/MS analyses of the most abundant peptides, choosing the
most intense multiply-charged ions with dynamic exclusion for
120 s. MS data were processed using Data Analysis software
(Bruker) and theautomatedMatrix ScienceMascotDaemonserver
(v2.1.06). Protein identifications were assigned using the Mascot
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databases restricting the search to teleostei, allowing a mass
tolerance of 0.4 Da for both MS and MS/MS analyses. In addition,
the search consistedof a carbamidomethyl fixedmodificationand
a variable oxidation.Fig. 1 – Histopathological scoring of mean lesion scores in
relation to week post challenge with SAV in pancreas (Pan),
heart (HT), red muscle (RM) and white muscle (WM) of
salmon (n = 9 per time point).3. Results
3.1. Virology, serology and RT-PCR
Cohabitant fish were SAV free before introduction of Trojan
shedders, as determined by virus isolation, virus neutralization
and RT-PCR (Table 1). Post introduction there was a subsequent
horizontal spread of the viral infection with the majority of
sampled fish being infected by week 4.
3.2. Histopathology of pancreas disease
Negligible mortality was observed pre-and post trial. The
development of lesions over time is illustrated in Fig. 1, which
shows mean lesion scores for each tissue at each sampling
point. The pancreas was the first tissue to develop lesions at
week 2 and was also the slowest to recover, with a minority of
samples still not fully recovered by week 12. Conversely, the
heart demonstrates an extremely quick recovery, with a peak
in lesion severity in fish sampled in week 4 and then a rapid
recovery. Since this study was based upon a cohabitation
model individuals were likely to be at different stages in the
disease process at each sampling point due to variation in the
time of infection. The histopathological damage to red and
white muscle was more delayed with the peak damage
occurring at 6 and 8 weeks respectively.
3.3. Profiling changes in the serum proteome
There were a number of clearly visible differences in the
serum proteome over the 12 week period of the trial,
illustrated in Fig. 2 where sample gels from each of the nine
sampling time points can be seen. However, to quantify andTable 1 – The percentage of samples from salmon
sampled at each time point that gave positive results for
SAV infection detected by reverse transcriptase
polymerase chain reaction (RT-PCR), virus identification
(SAV) and virus neutralisation (VN). Where ‘–’ indicates
that testing was not carried out.
Sampling time
point
Positive samples (% of total)
RT-PCR SAV VN
W0 – 0 0
W2 75 – –
W3 87 – –
W4 97 13 27
W5 88 2 67
W6 – – –
W8 – – –
W10 – – –
W12 – – –identify changes, scanned 2D-PAGE gel images from each
sampling time point were compared using ‘SameSpots’
software to identify protein spots which were differentially
expressed in the serum as a result of PD. In total, 894 spots
were identified by the SameSpot software of which 72 spots
were found to differ significantly over the course of infection
(Fig. 3). These were excised for peptide mass fingerprinting
from the gel where they showed greatest intensity. Protein
identification following DEAMON/MASCOT searching is given
in Table 2. Spot intensities at each time-point were analysed
using Hierarchical Cluster Analysis to more clearly identify
whether an association with disease progression over time
could be identified (Fig. 1) and to group proteins which
possessed similar expression profiles (Fig. 4). Fig. 4 also lists
spot numbers and their corresponding identities obtained by
ion trap mass spectrometry analysis of excised spots.
The dendrogramat the top of Fig. 4 shows the relationship of
the spot intensities at the nine time points illustrating
progression of the infection. There was a clear separation
between those recorded from 0 to 4 wpc and those recorded
from 5 wpc onwards. Comparison of the proteome at 12 wpc
with those prior to 4wpc indicated a return to homeostasis. The
overall fold increase or decrease in spot intensities from basal
level (week 0) for upregulated and downregulated proteins
respectively is shown in Table 2. Whilst most proteins and
enzymes increased in their abundance there were also a
number of proteins that declined in abundance (e.g. albumin).
3.4. The relationship between tissue pathology and the
serum proteome
The relationship between disease pathology and protein
abundance, given by spot intensities, was examined by
multilinear regression general linear model (GLM) analysis of
mean pathological scoring and allmean spot intensities at each
sampling time point. Table 3, which lists spot numbers and
their corresponding protein identity, also indicates the
probability (Pr > F) that a given spot expression profile is linked
Fig. 2 – Sample images of 2-dimension electrophoresis gels from all sampling time points from week 0 to 12 post challenge.
From left to right: Top row = Week 0, 2 and 3 images. Middle row = Week 4, 5 and 6 images. Bottom row = Week 8, 10 and 12
images.
Fig. 3 – Protein spots identified on 2-dimension electrophoresis as being as being differentially expressed following infection
superimposed on a week 0 image. Molecular weight (MW) is indicated on protein standard ladder in kilodalton (kD) and
isoelectric point (pI) range also shown.
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Table 2 – Protein spots showing maximum fold increase in spot intensity during the 12 weeks post infection, where
negative symbol (-) indicates a fold decrease in spot intensity, compared to pre-infection on week 0.
Spot
Number
Identification (Uniprot Reference) Max.
Fold
Change
Estimated
pI
Estimated
MW (kD)
MOWSE
Score
Peptide
Matches
%
coverage
19 Serotransferrin II + Ig heavy chain C region
(TRF2SALSA + A46533)
3.1 6.91 112 821, 65 43, 2 38, 5
32 C1 inhibitor (Q70W32) 5.4 5.21 97 137 6 14
43 Serotransferrin II (TRF2SALSA) 4.5 7.36 91 527 14 19
45 Complement factor H (Q2L4Q6) 10.4 8.37 91 79 2 3
47 Alpha-2 enolase-1 + Complement factor H
(Q9DDG6 + Q2L4Q6)
3.2 7.52 90 111, 94 3, 3 9, 3
74 No significant identification 4.4 4.33 81
98 Apolipoprotein A-I precursor (JH0472) 2.6 4.96 76 113 5 23
146 Complement component C9 (Q4QZ25) 2.2 5.2 70 226 7 17
150 Hemopexin-like protein (P79825) 9.6 4.22 68 64 3 9
151 Transferrin + Ig heavy chain C region
(T11749 + A46533)
1.5 7.27 68 967, 139 32, 4 35, 12
201 Antithrombin + Complement component C9
(Q9PTA8 + Q4QZ25)
- 2.8 5.43 59 156, 196 8, 6 14, 21
220 Hemopexin-like protein + Beta-actin
(P79825 + Q4U1U5)
2.5 6.57 57 166, 107 3, 3 8, 12
224 Hemopexin-like protein (P79825) 2.2 7.5 56 150 7 16
227 Hemopexin-like protein (P79825) 1.5 6.06 56 128 11 14
249 Serotransferrin II (TRF2SALSA) 5.4 8.36 51 101 3 7
260 Serum albumin 2 + Serum albumin 1
(ABONS2 + ABONS1)
- 1.7 4.77 50 364, 320 14, 13 24, 20
299 Enolase (Q7ZZM5) 5 8.03 47 308 14 25
313 Pyruvatekinase (Q8QGU8) 3.5 7.58 46 155 6 11
317 Alpha-2 enolase-1 (Q9DDG6) 7.6 7.94 45 648 37 53
326 Alpha-2 enolase-1 (Q9DDG6) 5.6 7.78 45 560 23 42
328 Alpha-2 enolase-1 (Q9DDG6) 5.2 7.27 44 292 15 39
342 Serum albumin 2 (ABONS2) - 11.1 5.54 44 666 32 31
357 Serum albumin 2 + Complement factorB/C2-B
(ABONS2 + Q9DEC8)
2.4 5.2 41 302, 49 13, 3 18, 3
360 Alpha-2 enolase-1 (Q9DDG6) 15.3 7.77 41 624 28 44
368 Serum albumin 2 + Serum albumin
1(ABONS2 + ABONS1)
- 2.8 4.88 40 318, 295 15, 13 19, 16
381 Alpha-2 enolase-1 + Creatine kinase
(Q9DDG6 + Q8JH38)
2.8 7.28 38 704, 101 30, 5 28, 14
386 Aldolase (Q804Y1) 13.8 8.72 38 108 3 23
388 Aldolase (Q804Y1) 8.1 8.62 38 94 1 9
391 Muscle-type creatine kinase CKM1 (Q8JH39) 5.1 7.35 38 252 9 17
393 Glyceraldehyde3-phosphate dehydrogenase (O42259) 15.7 8.79 38 102 9 36
394 Aldolase A (Q8JH72) 11.8 8.82 38 231 11 20
395 Serotransferrin II (TRF2SALSA) 2.2 6.56 38 210 5 9
440 Alpha-2 enolase-1(ABONS1) 4.5 6.64 36 164 3 9
442 Creatine kinase (Q98SS7) 3 7.61 36 218 6 17
444 Complement C3-1 + Cystein proteinase inhibitor
protein (P98093 + Q70SU8)
- 3.1 5.4 36 156, 36 10, 2 6, 12
450 Serotransferrin II precursor (TRF2SALSA) - 2.6 6.79 36 444 15 23
463 Glyceraldehyde3-phosphate dehydrogenase (Q90ZF1) 10.6 8.98 34 247 18 41
472 Serum albumin 2 (Q98SS7) - 3.7 4.79 34 323 12 19
473 Fructose-bisphosphate aldolase (Q4RVI9) 16.9 8.81 34 98 1 3
477 Aldolase A (Q8JH72) 10.1 8.7 33 130 5 18
479 Glyceraldehyde 3-phosphate dehydrogenase (O42259) 7.1 8.43 33 190 20 34
493 Glyceraldehyde 3-phosphate dehydrogenase (O42259) 11.6 8.18 33 147 13 12
494 Glyceraldehyde 3-phosphate dehydrogenase (Q90ZF1) 15.3 8.2 33 280 13 45
499 Proteasome (Q7ZVP5) 8.2 8 32 35 1 1
500 Aldolase A (Q8JH72) 15.4 8.58 32 110 4 17
509 Serotransferrin II (TRF2SALSA) - 2.6 6.78 31 250 11 18
529 Alpha-2 enolase-1 (Q9DDG6) 5 7.07 30 80 3 11
545 Serotransferrin II (TRF2SALSA) - 5.7 6.57 28 64 3 5
548 Serum albumin 1 (P21848) - 7 6.29 27 122 3 7
556 Serotransferrin 2 + Immunoglobulin light chain
(TRF2 + AAG18369)
- 5.3 6.36 27 404,150 18, 7 16, 33
565 Hemopexin-like protein (P79825) 7.8 6.26 26 51 4 8
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Table 2 (continued)
Spot
Number
Identification (Uniprot Reference) Max.
Fold
Change
Estimated
pI
Estimated
MW (kD)
MOWSE
Score
Peptide
Matches
%
coverage
568 Transferrin (Q8AYG2) - 3.6 7.36 26 285 12 36
575 Apolipoprotein A-I + Ig light chain precursor
(JH0472 + AAG18369)
1.8 6.62 26 188, 76 8, 4 28, 24
584 Malatedehydrogenase1a (B8JMZ0) 5.8 8.88 25 70 1 4
586 Apolipoprotein A-I (JH0472) 1.9 4.76 25 262 8 27
598 Apolipoprotein A-I (JH0472) 1.5 5.15 24 257 19 42
602 No significant identification. 3.6 8.63 24
608 Triosephosphate isomerase (Q70I40) 2.8 8.5 24 170 6 22
613 Serum albumin 2 (ABONS2) 2.4 8.1 24 488 19 23
623 Triosephosphate isomerase + Ig light chain
(Q70I40 + AAG18369)
3.4 8.57 23 305, 109 10, 5 49, 19
624 Triosephosphate isomerase (Q70I40) 2.4 8.1 23 194 11 50
626 Ig light chain (AAG18369) 2.4 7.26 23 190 8 24
627 Triosephosphate isomerase + Ig light chain
constant region (Q70I40 + AAN40739)
2.6 7.53 23 131, 87 5, 4 22, 25
628 Triosephosphate isomerase (Q70I40) 3.9 7.85 23 432 19 65
642 Apolipoprotein A-I (JH0472) 3.8 5.57 21 435 27 37
656 Serotransferrin II (TRF2SALSA) - 5.3 8.63 20 251 6 10
668 Apolipoprotein A-I (JH0472) - 4.8 5.17 19 325 19 34
669 Apolipoprotein A-1 (JH0472) - 4.1 5.42 19 221 14 32
687 Serotransferrin II (TRF2SALSA) 4.6 7.93 18 199 7 12
702 Prostaglandin D synthase (Q9DFD7) - 3.3 8.16 17 82 1 9
738 Putative oncoprotein nm 23 (Q2L4Q6) 7.2 7.3 14 58 11 22
741 Nucleoside diphosphate kinase (Q7ZZQ7) 4.6 6.9 14 58 8 22
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regarded as significant.
In addition, expression profiles were plotted on a graph for
each protein (see Supplementary Information) against the
mean pathology pattern of each tissue sampled. Fig. 5
illustrates the relationship between mean white muscle
histopathology results and the spot intensity of protein spot
313, identified as pyruvate kinase between weeks 2 and 12.
Week 0 was removed from this analysis as white muscle
showed no lesions at this time point. Graphs for other
proteins are given as extra material.
The alterations in serum proteins as a result of PD fell into
either of two categories. The first of these were proteins which
demonstrated a change in serum abundance (spot intensity)
that was associated with damage to a particular tissue or
tissues where an increase in intensity was significantly
related to the damage. In contrast there were proteins for
which the abundance change was not associated directly with
tissue damage and were likely to be present in serum as
humoral components of host defence (Table 3). Among
the group of proteins, the concentration of which was associated
with tissue pathology, were a number of enzymes described by
ontology as being involved in intracellular pathways. These
include creatine kinase, enolases, triosephosphate isomerase,
and malate dehydrogenase 1a. The second group of proteins,
alteration of whichwere not related to tissue damage, included a
number of well defined (in other systems) humoral
constituents of the immune response such as a number of
complement components, hemopexin, transferrin, and
apolipoprotein.4. Discussion
4.1. Monitoring pancreas disease via proteomics
The analysis of spot profiles at weekly sampling points (Fig. 3)
demonstrated that the serum proteome of salmon was altered
markedly in response to SAV3. In addition, the heat map of
proteome responses following the 2-DE showed a distinct
change in the serum proteome between pre and post week 4
(Fig. 4), with the exception of week 12, which clustered with
samples collected between weeks 1 and 4; thus, indicating the
near return of homeostasis. These results corresponded with
the histopathological results (Fig. 1) indicating that 2DE could
be used as a useful investigative approach to monitor PD.
Furthermore, using both histopathology and proteomic
approaches allowed proteomic results to be separated into
proteins and enzymes which rise or fall in association with
tissue damage and those which were part of the host response
to SAV3 (Table 3) as their alteration in intensitywas unrelated to
the histopathology score. The use of hierarchical clustering to
analyse spot intensities effectively highlighted the common
responses within groups of protein spots and clearly illustrated
a temporal trend in the dataset. It is important to note that this
analysis was carried out using pooled samples, determined by
time point. Whilst, there is an argument for using biological
replicates using individual fish it was considered that pooling
samples prior to electrophoresis was the optimal approach. As
this study was a cohabitation trial there are, due to infection
dynamics, fish at various disease stages which would, when
Fig. 4 – Arraystar heat map representing the results of Hierarchical Clustering of spot intensities. The relationships among
different sampling time-points are illustrated as a dendrogram at the top of the diagram. The right-hand side gives spot
number and corresponding identity from MS/MS which are grouped by profile similarity with a dendrogram showing the
relationships on left-hand side. The heatmap is on a colour scale where low protein abundance is represented in blue and high
abundance in red.
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replicates and pooling of samples was thus required to make
the study feasible. Moreover, as this experimentalmethodology
simulates conditions during an outbreak of PD at an aquaculture
site it was decided that pooling would allow for the analysis of
changes at a site as a whole.
4.2. Biomarkers of tissue pathologies
The use of histopathology in conjunctionwith a 2-DE proteomic
approach allowed statistical analysis to be carried out to test the
hypothesis that the expression profile of specific proteins was
correlated with the pathology of examined tissues. Analysis of
this relationship allowed the probable identification of the
tissue source of the identified serum proteins.
The abundance of only one spot significantly correlated to
the histopathology results of heart damage. This was spot 656
and was identified by MS as the Serotransferrin II. The
expression profile of this protein was significantly related to
the pathological damage to the heart. The lack of additional
biomarkers of heart damage was most likely because the
abundances of other potential protein biomarkers were notraised sufficiently in the serum to be detected by the proteomic
methodology used.
The pathological damage to the pancreas aswell as thewhite
and red skeletalmuscle wasmuchmore pronounced and longer
lasting than that observed in the heart (Fig. 1), and there were
more protein spots correlated with histopathology lesion scores
(Table 3). Six spots were found to be correlated with damage to
pancreas and also correlating to damage to white and red
muscle. Three of the spots were identified as triosephosphate
isomerase (spots 608, 627, and 628) and were in close proximity
on 2-DE gels, whilst the remaining three spots were identified as
creatine kinase, alpha-2 enolase-1, and serotransferrin (spots
391, 529 and 545 respectively). Enolase and creatine kinase are
enzymes of glycolysis and were presumably derived from the
damage to muscle. Transferrins are found in the fibroblasts of
the pancreas and skeletal muscles thus it was possible that this
serotransferrin was membrane bound/intracellular transferrin
isoform that leaked into the circulation due to tissue damage.
Only three spots were exclusively correlated with damage to the
pancreas (Table 3). One was identified as albumin while the
other two spots contained apolipoprotein (spot 260, 575 and 598
respectively). However, as their spot intensity during PD
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as biomarkers of pancreas damage.
The two types of skeletal muscle studied in this
investigation were white and red muscle. These muscle fibres
are differentiated by two functional characteristics, specifically
contractile speed and metabolic activity. White fibres (fast)
possess a higher action potential due to the quicker generation
of ATP by glycolysis compared to red (slow) fibres which in
general terms generate ATP by oxidative (aerobic) processes.
However, glycolysis does occur in red muscle fibres, which
explains the finding that many glycolytic enzymes were found
to rise in serum spot intensities at the peak of PD pathological
damage to bothmuscle types (Table 3). Many of these glycolytic
enzymes have been observed and studied in both muscle types
in salmon [25], and have been found to possess higher activity
levels in white muscles than in red [26,27]. Only two spots,
identified as Glyceraldehyde-3-phosphatedehydrogenase and
aldolase A (479 and 500 respectively), were exclusively
identified as related to red muscle pathology. Rather than
highlighting themetabolic differences between these two types
of Salmo salar skeletal muscle these differences may indicate
that red and white muscle fibres display a differential
expression of multiple isozymes of these enzymes.
Conversely this study identified a number of possible unique
biomarkers ofwhitemuscle damagedue to SAV3 as spots 43, 45,
249, 299, 313, 326, 328, and 738 (for protein identification see
Tables 2 or 3) were related to histopathological change in white
muscle. An explanation of this observation is that in Atlantic
salmon the white muscle mass is much greater than red.
Complement factor H (CFH) was one of the proteins found in
this study to be a possible biomarker of white muscle damage;
in fact all three spots identified as this protein (45, 47 and 738)
possess expression profiles that correlated significantly with
white muscle pathology. This glycoprotein is an important
component of the innate immune system with a number of
known functions related to it being a regulator of the
complement system alternative pathway [28] and acting to
reduce local concentrations of toxic products of inflammation
[29]. The expression profile of all three spots which contained
CFH was that of a continuous rise in intensity until a peak at
week 8wpc and then a sharp fall to near basal intensities in
week 12.
4.3. Humoral components of the serum response during
pancreas disease
Complement is a vital component of the immune system of
all animals. However, fish are unique in that their comple-
ment components exhibit a greater diversity than that of
those observed in the mammalian system [30]. In addition to
Complement Factor H described above, other Complement
components were identified by 2DE and found to change
following SAV3 challenge in salmon but without a correlation
to histopathology. Thus complement components C3, C9,
complement factor B, and the complement inhibitor C1 (spots
444, 146, 357 and 32 respectively), which have been previously
characterised as part of the fish innate immune system,
were identified in protein spots on 2DE. Interestingly the
complement membrane attack complex (MAC), of which C9 is
a pivotal component, damages the envelope of envelopedviruses [31]. Moreover, it has been shown that salmonid
antibodies are dependent on the presence of complement to
neutralize viral hemorrhagic septicemia virus (VHSV) and
infectious hematopoietic necrosis virus (IHNV) both of which
are enveloped rhabdoviruses [30]. Given that SAV is also an
enveloped virus it is possible that complement also plays a
role in its neutralization by Atlantic salmon antibodies in vivo.
The expression profiles of C3 and complement factor B fell
significantly at 5wpc whilst at the same time fractions of
immunoglobulins rose sharply, (for example spot 626), which
may have indicated that as immunoglobulins were synthesised
to combat SAV, complement components declined in their
serum concentration. In contrast, the expression profile of C1
inhibitor was substantially different from these previously
discussed complement components (Fig. 3). The late peak in
serum abundance of this protein at 10 wpc may indicate that
in the latter stages of disease recovery (Fig. 4) it was
advantageous to inhibit complement activation due to the
harmful effects of the alternative pathway andMAC can have
on host tissues [32].
Hemopexin-like protein (spots 150, 220, 224, 227 and 565)
was found to be significantly altered during SAV3 infection. In
mammalian specieshemopexin is anacute phase protein (APP),
synthesised in hepatocytes and extra-hepatocytic sites to be
secreted into circulation, and possesses a high affinity for free
circulating haem thus facilitating its clearance [33]. Hemopexin
in teleostei is usually referred to as hemopexin-like protein and
has been studied at a genetic level by a number of groups. Its
expression is highly up regulated during bacterial infections of
Atlantic salmon [34] and rainbow trout [35] with the proposal
that hemopexin-like protein is up regulated inorder to clear free
haem from the circulation which would be detrimental to the
proliferation of bacteria. In this study the expression profiles of
the hemopexin-like protein spots was also found to change
following infection. The first four of these spots were in close
proximity and exhibited very similar expression profiles
remaining near basal week 0 levels until at 5wpc they increased
sharply and reached their peak intensity at 10wpc and started
to fall again by 12wpc. This may have indicated an increase in
serum haem concentration during PD with higher levels of
hemopexin being synthesised to aid its clearance. In other
teleost species two isoforms of hemopexin-like protein have
been identified. For instance, medaka (Oryzias latipes) possesses
two hemopexin-like proteins which differ not only in their
tissue expression locations but also in their ability to bind heam
[36]. Interestingly, spot 565 showed the opposite from these
previously discussed spots in terms of expression profile.
Despite also displaying early stable expression levels it fell
sharply in intensity at 5wpc and continued to fall until 10wpc
before starting to rise. Therefore, it is possible that Atlantic
salmon also possess two isoforms of hemopexin-like protein
with the first contained in spots 150, 220, 224 and 227 and the
second located in spot 565. However it is possible that
alterations in the hemopexin-like protein spots, especially for
the lowermolecular weight spot 565, could be due to unspecific
degradation of proteins of higher molecular weight. It was
notable that the matched peptides profiles were similar
between the hemopexin-like spots so that the differences in
these protein spots could be due to post translational
modification or degradation. However it is possible that there
Table 3 – Probability (P) of relation between change in protein spot intensity and histopathology of tissues in salmon
infected with SAV.
Probability (P)
Spot
number
Identification Pancreas Heart Red
muscle
White
muscle
19 Serotransferrin II + Ig heavy chain C region (TRF2SALSA + A46533) 0.4775 0.7044 0.642 0.8544
32 C1 inhibitor (Q70W32) 0.542 0.3536 0.9656 0.3992
43 Serotransferrin II (TRF2SALSA) 0.0904 0.8329 0.204 0.0166
45 Complement factor H (Q2L4Q6) 0.3102 0.5645 0.1132 0.0061
47 Alpha-2 enolase-1 + Complement factor H (Q9DDG6 + Q2L4Q6) 0.0241 0.7643 0.0663 0.0059
74 No significant identification 0.2794 0.5719 0.4255 0.1125
98 Apolipoprotein A-I precursor (JH0472) 0.2179 0.5856 0.474 0.1619
146 Complement component C9 (Q4QZ25) 0.1032 0.6175 0.8862 0.9013
150 Hemopexin-like protein (P79825) 0.872 0.3269 0.7833 0.804
151 Transferrin + Ig heavy chain C region (T11749 + A46533) 0.0786 0.8847 0.5434 0.3814
201 Antithrombin + Complement component C9 (Q9PTA8 + Q4QZ25) 0.5868 0.5314 0.5774 0.9455
220 Hemopexin-like protein + Beta-actin (P79825 + Q4U1U5) 0.2798 0.4227 0.5775 0.1481
224 Hemopexin-like protein (P79825) 0.2104 0.9728 0.857 0.7601
227 Hemopexin-like protein (P79825) 0.077 0.8458 0.5829 0.4513
249 Serotransferrin II (TRF2SALSA) 0.2894 0.5577 0.1483 0.0339
260 Serum albumin 2 + Serum albumin 1 (ABONS2 + ABONS1) 0.0291 0.1971 0.4523 0.8357
299 Enolase (Q7ZZM5) 0.1996 0.5102 0.1088 0.0032
313 Pyruvatekinase (Q8QGU8) 0.0806 0.8639 0.0559 0.0039
317 Enolase 1 (Alpha) (Q6GMI7) 0.1688 0.6918 0.0963 0.0042
326 Alpha-2 enolase-1 (Q9DDG6) 0.1489 0.6904 0.0853 0.0061
328 Alpha-2 enolase-1 (Q9DDG6) 0.2178 0.5131 0.1028 0.0013
342 Serum albumin 2 (ABONS2) 0.371 0.1541 0.8433 0.3281
357 Serum albumin 2 + Complement factorB/C2-B (ABONS2 + Q9DEC8) 0.1225 0.1539 0.71 0.6958
360 Alpha-2 enolase-1 (Q9DDG6) 0.1997 0.7136 0.047 0.0002
368 Serum albumin 2 + Serum albumin 1 (ABONS2 + ABONS1) 0.0766 0.0806 0.7414 0.6659
381 Alpha-2 enolase-1 + Creatine kinase (Q9DDG6 + Q8JH38) 0.0618 0.9464 0.0272 0.0041
386 Aldolase (Q804Y1) 0.1753 0.911 0.0229 0.0204
388 Aldolase (Q804Y1) 0.153 0.7466 0.0532 0.0752
391 Muscle-type creatine kinase CKM1 (Q8JH39) 0.0462 0.7088 0.004 0.0009
393 Glyceraldehyde3-phosphate dehydrogenase (O42259) 0.1131 0.9435 0.0028 0.0002
394 Aldolase A (Q8JH72) 0.1324 0.9747 0.0067 0.0003
395 Serotransferrin II (TRF2SALSA) 0.0732 0.7892 0.4174 0.1811
440 Alpha-2 enolase-1 (ABONS1) 0.0534 0.8544 0.0097 0.0006
442 Creatine kinase (Q98SS7) 0.0536 0.9545 0.0334 0.0007
444 Complement C3-1 + Cystein proteinase inhibitor protein (P98093 + Q70SU8) 0.3808 0.3852 0.8427 0.4569
450 Serotransferrin II precursor (TRF2SALSA) 0.0744 0.1147 0.8475 0.8393
463 Glyceraldehyde3-phosphatedehydrogenase (Q90ZF1) 0.1712 0.8982 0.0287 0.0277
472 Serum albumin 2 + Creatine kinase (ABONS2 + Q98SS7) 0.2774 0.2544 0.7464 0.3222
473 Fructose-bisphosphate aldolase (Q4RVI9) 0.1771 0.8644 0.0292 0.0336
477 Aldolase A (Q8JH72) 0.1181 0.7005 0.0143 0.0255
479 Glyceraldehyde 3-phosphatedehydrogenase (O42259) 0.0972 0.4788 0.0307 0.1032
493 Glyceraldehyde 3-phosphatedehydrogenase (O42259) 0.2358 0.7868 0.0975 0.1501
494 Glyceraldehyde 3-phosphate dehydrogenase (Q90ZF1) 0.271 0.8078 0.132 0.2332
499 Proteasome (Q7ZVP5) 0.1454 0.6439 0.0706 0.1262
500 Aldolase A (Q8JH72) 0.1836 0.7625 0.039 0.0693
509 Serotransferrin II (TRF2SALSA) 0.1302 0.1569 0.9378 0.5525
529 Alpha-2 enolase-1 (Q9DDG6) 0.0105 0.1837 0.0004 0.0232
545 Serotransferrin II (TRF2SALSA) 0.01 0.1764 0.0002 0.0215
548 Serumalbumin 1 (P21848) 0.381 0.1562 0.7586 0.2887
556 Transferrin + Immunoglobulin light chain (Q8AUU0 + AAG18369) 0.1617 0.063 0.7479 0.5452
565 Hemopexin-like protein (P79825) 0.1514 0.0657 0.7578 0.6317
568 Transferrin (Q8AYG2) 0.1625 0.079 0.6619 0.7647
575 Apolipoprotein A-I + Ig light chain precursor (JH0472 + AAG18369) 0.0124 0.115 0.3685 0.7495
584 Malate dehydrogenase 1a (B8JMZ0) 0.0555 0.7354 0.0006 0.0001
586 Apolipoprotein A-I (JH0472) 0.1272 0.781 0.3957 0.1807
598 Apolipoprotein A-I (JH0472) 0.018 0.3991 0.3503 0.4654
602 No significant identification 0.0931 0.8462 0.0318 0.0005
608 Triosephosphate isomerase (Q70I40) 0.0134 0.6271 0.0079 0.0029
613 Serum albumin 2 (ABONS2) 0.1367 0.6988 0.1639 0.0516
623 Triosephosphate isomerase + Ig light chain (Q70I40 + AAG18369) 0.1508 0.5987 0.0971 0.0068
624 Triosephosphate isomerase (Q70I40) 0.0893 0.8886 0.1385 0.0628
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Table 3 (continued)
Probability (P)
Spot
number
Identification Pancreas Heart Red
muscle
White
muscle
626 Ig light chain (AAG18369) 0.1144 0.7554 0.1929 0.0606
627 Triosephosphate isomerase + Ig light chain constant region (Q70I40 + AAN40739) 0.0396 0.6455 0.0066 0.0115
628 Triosephosphate isomerase (Q70I40) 0.0082 0.3003 0.0001 0.0047
642 Apolipoprotein A-I (JH0472) 0.4075 0.7725 0.675 0.6736
656 Serotransferrin II (TRF2SALSA) 0.0929 0.0296 0.7203 0.6526
668 Apolipoprotein A-I (JH0472) 0.2306 0.1865 0.8973 0.4736
669 Apolipoprotein A-1 (JH0472) 0.5808 0.4595 0.5278 0.3262
687 Serotransferrin II (TRF2SALSA) 0.1577 0.0552 0.8437 0.5952
702 Prostaglandin D synthase (Q9DFD7) 0.1102 0.356 0.2959 0.4512
738 Putative oncoprotein nm 23 (Q2L4Q6) 0.1136 0.9017 0.0695 0.0056
741 Nucleoside diphosphate kinase (Q7ZZQ7) 0.0736 0.8809 0.0467 0.007
433J O U R N A L O F P R O T E O M I C S 9 4 ( 2 0 1 3 ) 4 2 3 – 4 3 6could be two homologous isoforms thus more work is
required to ascertain if, as in goldfish, salmon possess multiple
hemopexin isoforms.
A total of 13 protein spots, differentially expressed during PD,
were identified as transferrin (Tf) (Fig. 3). This glycoprotein is one
of several humoral proteins with an affinity to iron. This iron
binding by Tf facilitates the transport of iron from the circulation
to cells [37,38] thus preventing a potentially toxic iron build up,
although other functions are known [39]. The intensities of 4 of
the 13 Tf spots had a significant relationshipwith tissue damage
(pancreas and skeletal muscle) and have been previously
discussed. However, the change in expression of nine Tf spots
did not exhibit such a relationship to tissue damage, and were
thus deemed components of the immune system response to
SAV infection. Of these Tf spots number 151 was by far the
largest (in terms of area),migratedwith the highestMr (~68 kDa)
and remained at a relatively constant expression level until
between 8 and 10wpc at which point its expression increased
sharply only to fall slightly by 12wpc. This spot was presumably
the main protein constituent of Tf in the serum and is the fullFig. 5 – Plotting spot 313 (pyruvate kinase) mean intensity and m
sampling time points. Open circles plot histopathology scores anlength isoform. Other spots identified as Tf were smaller in size
with lowerMr than spot 151. These could have been degradation
products, although Stafford et al. [39,40] have shown that certain
transferrin fragments may not be just simply degradation
products to be eliminated from the circulation, but play a
significant role in the innate immune system of fish. These
studies demonstrated the ability of transferrin fragments (but
not full length transferrin) of goldfish (Carassius auratus) to
induce nitric oxide (NO) activation ofmacrophageswhich is vital
in viral disease recovery since NO is a potent antiviral-agent and
immune system modulator [41]. This observation of multiple
transferrin fragments with different expression profiles may
also help explain the considerable variability in the reporting of
transferrin as either a positive or negative APP [38] in the fish
immune system as certain approaches in studies may or may
not detect these fragments in terms of total transferrin.
However, given the large number of spots (13 in total) which
contained the protein it cannot be overlooked that, as with other
proteins, many of these change in concentration due to
unspecific degradation.ean histopathological scoring of white muscle against
d filled circles plot spot intensity at a given time point.
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3-phosphate dehydrogenase (GAPDH) within cells can initiate
a cascade ultimately ending in apoptosis of cells [42].
However, this study not only found GAPDH spots associated
with tissue pathologies, but also two spots (493 and 494)
which rose dramatically in intensity at 5wpc reaching
their peak expression at 6wpc before falling to near basal
intensities at 8wpc independently of tissue damage. Since
GADPH is regarded as an intracellular enzyme involved in
glycolysis this at first may be regarded as a surprising
observation. However, endogenous authentic GADPH has
previously been shown to be secreted outside of cells without
causing cell lysis by Yamaji et. al. [43] leading to the
hypothesis that it may possess a role in defence against
pathogens. Therefore, GADPH may be classed as an example
of a moonlight protein where a primarily intracellular protein
is secreted by cells and exhibits very different functions
extracellularly. Another intracellular enzyme found by 2DE
that may possess ‘moonlighting’ functions extracellularly was
the cytoplasmic glycolytic enzyme aldolase. This study found
two spots of aldolase that showed no relationship with
histopathology (Table 3) though whether there is a moonlighting
function of this enzyme is currently unknown.
Other proteins found in this study which increased in serum
concentration were the apolipoproteins. Apolipoprotein A-1
together with apolipoprotein A-II constitute the most abundant
circulating protein observed in teleosts. Its primary function is
the binding and transportation of lipids. However, other antiviral,
antimicrobial and anti-inflammatory defensive functions are
known [44,45]. This study identified four protein spots
containing apolipoprotein which did not exhibit a relationship
between expression profile and histology. Interestingly, despite
apolipoprotein being widely defined as negative acute
phase proteins in mammals all, except spot 668, exhibited a
steady increase in intensity with a peak at approximately 6 or
8wpc confirming previous results which found apolipoprotein to
be up regulated during fish disease [46,47]. This finding
demonstrated amajor difference in the expression of this protein
during disease in fish and may indicate additional functions of
the protein in fish that do not exist in mammalian
apolipoprotein. Despite this, as with transferrin, the possibility
of this expression profile being due to non specific degradation of
protein cannot be overlooked.
Protein synthesis can also fall during disease as a shift due
to a preferential synthesis of specific proteins. This is the
widely accepted hypothesis of why albumin (an extremely
abundant serum protein in all animals) is observed to act as a
negative acute phase protein in most instances. This study
also observed albumin to be down regulated following SAV3
challenge with the protein spots containing it showing a
steady decline in expression. Albumin hepatic expression has
also been shown to be reduced in other fish species during a
number of diseases [48]. Whilst albumin is a well known
negative acute phase protein two other proteinswhich declined
in serum abundance during PD are not as well documented.
These are antithrombin (spot 201) and prostaglandin-D synthase
(spot 702). Antithrombin inactivates several enzymes involved in
the coagulation system and thus down regulationmay allow the
benefits of coagulation during disease. Prostaglandin-D synthase
in serum has not been studied to any extent in fish or otherspecies immunity, although inhibition of the protein has been
shown to correlate with muscular necrosis [49] which may have
significance in PD and other viral diseases that cause necrosis of
muscle fibres.5. Conclusion
This histopathological and proteomic study of PD in Atlantic
salmon, Salmo salar, has identified numerous serum proteins
which are altered in abundance during the disease. A correlation
between pathology and changes in spot intensity of intracellular
proteins and enzymes was established, including variations in a
number of tissue specific isozymes. Furthermore alterations, not
associated with histopathology, were identified for components
of humoral immunity which were presumably involved in both
limiting the establishment of PD and aiding the return to
homeostasis. A number of proteins, including complement
components, apolipoprotein, hemopexin, and transferrin were
identified as increasing in serum concentration, whilst albumin
and antithrombin levels appeared to decrease during PD. Prior to
their use as biomarkers of either tissue damage or humoral
response in PD, the diagnostic value of these proteins should be
validated by complementary approaches, such as; western
blotting, immunohistochemistry and ELISA. However, the
proteomics approach described here could be used in to
investigate other disease challenge models to look for points of
similarity and difference between diseases of importance in
aquaculture to identify protein change most associated with
morbidity and death, and to deliver insights into disease
aetiology and identify mitigation strategies.Acknowledgements
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